Ionis Enters Licensing Deal With Recordati For Zilganersen Commercialization In Alexander Disease

Ionis Pharmaceutical entered a license agreement with Recordati for international commercialization rights to Zilganersen, a treatment for Alexander disease. The deal expands potential distribution for the drug outside the U.S. and supports Ionis' commercialization strategy. The announcement is positive for both companies, but the news is likely to have only a limited immediate share-price impact.

Analysis

Ionis Pharmaceutical entered a license agreement with Recordati for international commercialization rights to Zilganersen, a treatment for Alexander disease. The deal expands potential distribution for the drug outside the U.S. and supports Ionis' commercialization strategy. The announcement is positive for both companies, but the news is likely to have only a limited immediate share-price impact.